Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults With Prurigo Nodularis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 May 2021
Price :
$35
*
At a glance
- Drugs Serlopitant (Primary)
- Indications Prurigo nodularis; Pruritus
- Focus Registrational; Therapeutic Use
- Sponsors Menlo Therapeutics; VYNE Therapeutics
- 06 Apr 2020 Primary endpoint has not been met. (WI-NRS 4-point responder rate),according to a Menlo Therapeutics media release.
- 06 Apr 2020 Results published in the Menlo Therapeutics media release.
- 04 Mar 2020 Status changed from active, no longer recruiting to completed.